ADA-Predictor is a transparent clinical support tool for anti-drug antibody risk in biologic-treated autoimmune disease. It estimates immunogenicity risk using biologic class, methotrexate co-therapy, HLA-DQA1*05 status, prior biologic failure, inflammatory burden, smoking, disease duration, and BMI, then converts the result into a risk tier and therapeutic monitoring suggestion.
Chronic glucocorticoid therapy can suppress the hypothalamic-pituitary-adrenal axis, but clinicians need a transparent way to distinguish routine taper discomfort from clinically meaningful adrenal-insufficiency and adrenal-crisis risk. ADRENAL-TAPER integrates current prednisone-equivalent dose, exposure duration, taper speed, abrupt cessation, long-acting steroid exposure, morning cortisol, ACTH stimulation peak cortisol, symptoms, and physiologic stressors to produce a composite suppression/crisis score with a 95% uncertainty interval.
TACRO-CYP5 is a transparent bedside tacrolimus exposure-risk model for autoimmune disease. It combines CYP3A5 genotype, starting dose, kidney and liver context, interacting drugs, and monitoring readiness to distinguish underexposure from toxicity and support early trough-guided titration.
Peripheral neuropathy in systemic autoimmune rheumatic disease is clinically important but often diagnostically messy. The bedside question is rarely only whether neuropathy is present; it is whether the pattern suggests vasculitic neuropathy, small-fiber neuropathy, or a common metabolic or entrapment confounder that should be corrected before autoimmune attribution is made.
Systemic corticosteroids can precipitate insomnia, mood elevation, mania, depression, psychosis, or delirium. We describe STEROID-PSYCH, a transparent heuristic score that integrates steroid dose, pulse exposure, treatment duration, psychiatric history, sleep loss, delirium vulnerability, CNS inflammation, age, and acute medical instability to make psychiatric risk explicit before or during steroid therapy.
Wearable devices can capture physiology continuously, but autoimmune care still lacks a transparent bedside method for deciding when a cluster of changes in heart rate, heart-rate variability, oxygen saturation, and activity should count as a clinically meaningful flare signal rather than noise. We present VITALS-WATCH, a dependency-light Python skill that combines baseline-referenced wearable vital-sign summaries with Bayesian online change-point detection and a simple multi-channel flare score.
HANDROM is an executable clinical decision-support skill that estimates hand impairment from range-of-motion loss, grip and pinch weakness, inflammatory burden, pain/stiffness, and functional difficulty. It returns a severity category, uncertainty interval, referral recommendation, and red-flag notes for rheumatic disease care.
ANEMIA-IMMUNE stratifies anemia in autoimmune disease by combining hemoglobin severity, MCV, ferritin, transferrin saturation, CRP, reticulocytes, kidney function, bleeding signals, hemolysis signals, and myelosuppressive drugs into a transparent 0-100 concern score and phenotype label. The implementation is executable Python and is intended to support differential diagnosis of iron deficiency, inflammation/CKD-pattern anemia, mixed anemia, and probable marrow-suppression/hemolysis context.
LEF-WASH is a transparent clinical heuristic for reproductive-safety triage when leflunomide is active, recently stopped, or being cleared before conception in rheumatic and autoimmune disease. The bedside problem is not whether the drug was merely discontinued, but whether cholestyramine washout occurred, whether teriflunomide clearance below 0.
ANIFRO-HZ is an executable, transparent clinical decision-support skill for stratifying herpes zoster concern in systemic lupus erythematosus during or soon after anifrolumab exposure. The bedside problem is not only knowing that zoster risk exists, but recognizing when glucocorticoids, lymphopenia, nephritis-level co-immunosuppression, absent recombinant zoster vaccination, and early symptom patterns create a treatment context that should alter monitoring or escalation.
## Abstract Anticoagulation in antiphospholipid syndrome (APS) remains clinically contentious because the convenience of direct oral anticoagulants (DOACs) is not matched by uniform safety across APS phenotypes. The central bedside problem is not whether DOACs are ever usable, but whether a given patient sits in a high-risk phenotype where DOAC exposure is especially unfavorable.
Denosumab discontinuation creates a distinctive clinical hazard: vertebral-fracture risk can rebound rapidly when treatment is delayed or stopped without sequential antiresorptive therapy. This problem is especially relevant in rheumatology and glucocorticoid-treated osteoporosis, where missed injections may go unnoticed until new back pain or clustered vertebral fractures emerge.
RA-MODEL is an executable Python skill that consolidates standard rheumatoid arthritis disease-activity and function indices into one transparent longitudinal workflow. It computes DAS28-CRP, DAS28-ESR, CDAI, SDAI, Boolean remission, HAQ-DI, RAPID3, and a treat-to-target summary across serial visits.
Visual ischemic complications of giant cell arteritis (GCA) are among the most time-sensitive emergencies in rheumatology and ophthalmology because permanent vision loss can occur before diagnostic certainty is complete. GCA-VISION is an executable dependency-free Python skill that converts this bedside problem into a transparent 0-100 ocular ischemia risk-context score.
HCQ-QT is an executable Python skill for transparent QT-prolongation risk-context stratification before or during hydroxychloroquine therapy in rheumatic and autoimmune disease. It weights baseline QTc, sex-age context, kidney function, potassium and magnesium status, structural and arrhythmic cardiac history, bradycardia, concomitant QT-prolonging drugs, hydroxychloroquine dose intensity, and syncope or palpitations into a 0-100 concern score.
Osteonecrosis is a clinically meaningful but often underrecognized complication of systemic lupus erythematosus (SLE), especially after repeated pulse methylprednisolone exposure or sustained high cumulative glucocorticoid burden. The diagnostic problem is practical: early hip or groin pain may be normalized until structural injury is advanced, while the real risk context was created earlier by nephritis, steroid intensity, vascular-metabolic factors, and thrombosis biology.
PRES-LUPUS is an executable Python skill for transparent bedside risk-context stratification of posterior reversible encephalopathy syndrome in systemic lupus erythematosus. It addresses a real clinical recognition problem: when acute neurologic symptoms during lupus nephritis, severe hypertension, and high-intensity immunosuppression should trigger urgent PRES exclusion rather than delayed attribution to flare alone.
Autoimmune congenital heart block is a rare but high-consequence complication of anti-Ro/SSA pregnancies. NEO-LUPUS is an executable Python skill that converts the bedside surveillance problem into a transparent 0-100 risk-context score.
SRC-SHIELD is an executable Python skill for transparent scleroderma renal crisis risk-context stratification in systemic sclerosis. It weights diffuse cutaneous phenotype, early disease duration, anti-RNA polymerase III positivity, glucocorticoid exposure, new hypertension, creatinine rise, proteinuria, and microangiopathic features into a 0-100 concern score.
Occult Strongyloides stercoralis infection is an under-recognized safety problem in rheumatology and autoimmune care because clinically silent infection may accelerate into hyperinfection after glucocorticoids or other potent immunosuppression. STRONGY-GUARD is an executable Python skill that converts this bedside problem into a transparent 0-100 risk-context score using endemic exposure, eosinophilia, positive serology, positive stool/larvae, glucocorticoid intensity and duration, pulse methylprednisolone, rituximab/cyclophosphamide exposure, HTLV-1, compatible symptoms, gram-negative sepsis, current immunosuppression, and recent ivermectin treatment.